Deaths in SARS-Cov-2 Positive Patients in Italy: The Influence of Underlying Health Conditions on Lethality.
COVID-19
Italy
SARS-CoV-2
lethality
underlying health conditions
Journal
International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455
Informations de publication
Date de publication:
21 06 2020
21 06 2020
Historique:
received:
27
05
2020
revised:
18
06
2020
accepted:
19
06
2020
entrez:
25
6
2020
pubmed:
25
6
2020
medline:
3
7
2020
Statut:
epublish
Résumé
This study aims to underline the clinical characteristics of patients who died after testing positive for SARS-CoV-2 infection in one region of Italian and to evaluate the influence of underlying health conditions on the fatal outcome. A matched case-control study was designed by analyzing the data regarding positive subjects observed up to April 21, 2020. The case fatality rate was 7.9%, with a higher proportion of deaths in men than women. The specific standardized mortality ratio was 0.15-0.13 for males and 0.2 for females, showing that mortality is much lower than expected. Cardiovascular diseases, chronic lung diseases and diabetes mellitus showed a significant association with the outcome. Although the case fatality rate in Sardinia in regard to age and gender patterns seems to be similar to that for Italy as a whole, its quantitative value was far lower than the national one and possible explanations might include the genetic characteristics of the Sardinian population or the immediate closure of its borders as soon as the epidemic started. Our results highlighted that lethality is strongly dependent on the presence of multiple concomitant serious diseases. It is important to have epidemiological strategies for effective guidance on public health actions in order to improve chances of survival.
Identifiants
pubmed: 32575825
pii: ijerph17124450
doi: 10.3390/ijerph17124450
pmc: PMC7344703
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Nat Genet. 2018 Oct;50(10):1426-1434
pubmed: 30224645
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Int J Antimicrob Agents. 2020 Mar 20;:105949
pubmed: 32205204
Hum Mol Genet. 2000 Dec 12;9(20):2959-65
pubmed: 11115839
JAMA. 2020 Feb 24;:
pubmed: 32091533
JAMA Intern Med. 2020 Apr 7;:
pubmed: 32259190
Lancet Public Health. 2020 Jun;5(6):e310
pubmed: 32339478
Lancet. 2020 Mar 14;395(10227):e49-e50
pubmed: 32119824
JAMA. 2020 Mar 23;:
pubmed: 32203977
Exp Gerontol. 2004 Sep;39(9):1423-9
pubmed: 15489066
Acta Diabetol. 2017 Jan;54(1):9-17
pubmed: 27639869
J Thromb Haemost. 2020 May;18(5):1094-1099
pubmed: 32220112
Front Immunol. 2020 May 28;11:1208
pubmed: 32574270